Kornimate/medical-research-clean huggingface dataset:
a clinical study aims to assess the consistency of clinical efficacy in gastric cancer treatment and drug susceptibility outcomes using a novel drug susceptibility testing method

Conditions: Gastric Cancer; Organoids

Summary: the study is a real-world observational clinical study. patients diagnosed as gastric cancer through histopathology were screened and enrolled. before anti-tumor treatment, gastroscopy biopsy tissue specimens, surgical specimens, and malignant pleural effusion or ascites specimens, etc. are collected. the investigators will perform a drug sensitivity testing based on a novel drug susceptibility testing method to test the commonly used anti-tumor treatment regimens. patients were given conventional anti-tumor treatment according to the medical judgment of the doctors. finally, the investigator will evaluate the consistency of clinical efficacy in gastric cancer treatment and drug susceptibility outcomes.


Eligibility criteria:
inclusion criteria: 1. male or female, aged ≥ 18 and ≤80; 2. patients with gastric cancer diagnosed by histopathology; 3. patients who need neoadjuvant treatment; adjuvant therapy after radical surgery or palliative treatment; 4. fresh tumor tissue specimens or malignant pleural effusion or ascites can be obtained; 5. patients who sign the informed consent form, and are able to comply with the study period treatment process. exclusion criteria: 1. inability to follow the research protocol; 2. inability to obtain relevant fresh specimens by biopsy/surgery/puncture; 3. concomitant contraindications to chemotherapy; 4. pregnant or lactating women; 5. patients deemed inappropriate by investigators.
post-marketing safety study in st-segment elevation myocardial infarction (stemi) participants undergoing primary percutaneous coronary intervention (pci) procedure with visipaque® as the contrast medium

Conditions: Coronary Artery Disease; ST-segment Elevation Myocardial Infarction

Summary: the purpose of this study is to prospectively observe the incidence rate of acute kidney injury (aki), major adverse renal and cardiovascular events (marce) in participants who were diagnosed with st-segment elevation myocardial infarction (stemi) and have completed primary percutaneous coronary intervention (pci) procedure following an injection of iso-osmolar contrast medium iodixanol (visipaque) during the in-hospital period and up to 30 days post-pci follow-up period. the study will provide a better safety profile of visipaque as the contrast medium in pci procedure.


Eligibility criteria:
inclusion criteria: participants may be included in the study if they meet all of the following criteria: * the participant is over 18 years' old * the participant with st segment elevation myocardial infarction (stemi) diagnosis has completed primary percutaneous coronary intervention (pci) procedure and visipaque was used as the contrast medium in the procedure * the participant completed pre-procedural serum creatinine (scr) test at the same hospital where pci procedure was conducted, and the scr test should be conducted with the same methodology before and after the procedure * the participant has signed and dated the written informed consent form exclusion criteria: participants must be excluded from participating in this study if they meet any of the following criteria: * the participant has any contraindications to visipaque (e.g., manifest thyrotoxicosis, history of serious hypersensitivity reaction to iodinated contrast media) * the participant is pregnant or lactating * the participant has been previously enrolled in this study * the participant is currently under renal dialysis * the participant presents with a terminal (life expectation \<1 month), serious, or life-threatening disease, or any medical or psychiatric condition, or any condition where study participation may compromise the management of the participant * the participant has other reasons that in the judgement of the investigator is unsuitable for participation in the study
effects of telemonitoring on the outcome of heart failure patients after an incidence of acute decompensation

Conditions: Heart Failure

Summary: heart failure is the most rapidly rising cardiovascular disease and has come to be recognized as a growing epidemic. digital health interventions are the most recent iteration of an effort to promote individualized outpatient care through positive behaviour change theory. the uhn team has developed a highly automated and user-centered smartphone-based system, medly, which allows for the telemonitoring of patients diagnosed with heart failure. the purpose of this study will be two-fold: 1) to determine if the introduction of medly within two weeks of discharge will improve self-care management, quality of life, and clinical status, 2) to assess whether medly will lead to a potential reduction in 30 day readmission rates amongst hf patients in the toronto central local health integration network (tc lhin), without increasing the average length of stay or visits to the emergency department. these parameters will be measured as secondary outcomes.

heart failure is the most rapidly rising cardiovascular disease and has come to be recognized as a growing epidemic. digital health interventions are the most recent iteration of an effort to promote individualized outpatient care through positive behaviour change theory. the uhn team has developed a highly automated and user-centered smartphone-based system, medly, which allows for the telemonitoring of patients diagnosed with heart failure patients with heart failure will be provided with a smartphone and commercial home medical devices, such as a blood pressure monitor and weight scale. the measurements from the medical devices will be automatically sent to the smartphone, and from there to a data server at the hospital for analysis and storage. both clinicians and patients will be able to access these data and will be sent alerts by the system if the measurements are outside of the normal range. the system will be evaluated through interviews and comparing outcomes between the intervention and control groups.

Eligibility criteria:
inclusion criteria: * adults (18 years or older) * hospitalization for decompensated hf \> 48 hours * patient speaks and reads english adequately to provide informed consent and understand the text prompts in the application (or has an informal caregiver who can translate for them) * ability to comply with using medly (ex. able to stand on the weight scale, able to answer symptom questions, etc.) exclusion criteria: * dementia or uncontrolled psychiatric illness * residents of long-term care facilities * terminal diagnosis of any health condition with a life expectancy \< 1 year * patients who will require inpatient rehabilitation after discharge * participating in another clinical trial that may confound the results

Keywords: telemonitoring smartphone application
monocentric retrospective observational study on patients with macular degeneration

Conditions: Exudative Age-Related Macular Degeneration

Summary: main objective: the main objective of this retrospective observational study was to describe the evolution of visual acuity measured on etdrs (early treatment diabetic retinopathy study) scale, for patients with exudative age-related macular degeneration (armd), treated with lucentis, under real conditions of care, in terms of mean change of the best corrected visual acuity (bcva), measured at 24 months (± 4 weeks).


Eligibility criteria:
inclusion criteria: * patients with exudative-subfove armd, regardless the neovessel type or the initial visual acuity; 2 - patients treated in the department with intra vitreous injection of lucentis ® during the study period (08/2011 and 02/2013); 3 - if both eyes are eligible, both will be analyzed; exclusion criteria: 1. - patients who received, for the studied eye, a treatment with a vascular endothelial growth factor (vegf) other than lucentis ® in the three months preceding the start of the study. for those who received combination therapy, the nature of the treatment will be specified and taken into account in the subgroups for statistical analyzes; 2. - patients with high myopia or neovessel not related to exudative-armd;
risk factors for postoperative shoulder-tip pain after laparoscopic surgery undergoing general anesthesia

Conditions: Laparoscopic Surgery; Anesthesia

Summary: to find out the risk factors for postoperative shoulder-tip pain after laparoscopic surgery undergoing general anesthesia.

to find out the risk factors for postoperative shoulder-tip pain after laparoscopic surgery undergoing general anesthesia.besides,this research also aims to observe the incidence of postoperative shoulder-tip pain after laparoscopic surgery undergoing general anesthesia.

Eligibility criteria:
inclusion criteria: 1. patients over 18 years old (including 18 years old) having gynecologic or gastrointestinal or hepatobiliary surgery undergoing general anesthesia; 2. patients agreeing to participate in the study and sign the informed consent. exclusion criteria: 1. patients under 18 years age or having emergency laparoscopic surgery; 2. patients having laparoscopy but not undergoing general anesthesia; 3. patients undergoing laparoscopy and having hysteroscopy at the same time. 4. patients undergoing laparoscopy and having fistulostomy at the same time. 5. patients having regional thermoperfusion after laparoscopic surgery. 6. laparoscopy being needed to converse to laparotomy. 7. patients having shoulder pain or history of periarthritis of shoulder or long-term taking painkillers. 8. patients having severe psychological problem and unable to cooperate with our study. 9. patients being sent to icu for further treatment after operation. 10. patients being discharged within 2 days after operation and losing contact. 11. patients having another operation after laparoscopy. 12. patients taking another painkillers except using patient-controlled intravenous analgesia. 13. patients refusing to take part in this study.

Keywords: risk factor laparoscopic surgery postoperative shoulder pain
health literacy in people with chronic obstructive pulmonary disease

Conditions: Chronic Obstructive Pulmonary Disease

Summary: health literacy refers to personal and relational factors affecting a person's ability to acquire, understand and use information about health and health services. in a need assessment study it was found that, the health services need to focus on health literacy factors in the follow up of patients with chronic obstructive pulmonary disease (copd). thus, this project evaluate the effect a of a health literacy partnership health promotion intervention (hospital, municipalities, university) after discharge from hospital with the use of motivational interviewing and tailored follow-ups on re-admission, health literacy, self-management quality of life and cost in people with copd compared with usual care.


Eligibility criteria:
inclusion criteria: * diagnosed with copd, * above 18 years, * admitted to a medical department at the main intervention hospital, l * live in the sites belonging to the intervention hospital. exclusion criteria: * not diagnosed with copd, * not above 18 years, * not admitted to a medical department at the main intervention hospital, and * not living in the sites belonging to the intervention hospital. * cognitive failure * patients that are investigated or treated for cancer

Keywords: health literacy
randomized study of albendazole in patients with epilepsy due to neurocysticercosis

Conditions: Epilepsy; Cysticercosis

Summary: objectives: i. determine the effect of antiparasitic treatment with albendazole on the severity and duration of epilepsy due to neurocysticercosis. ii. determine the effect of a short course of albendazole on taenia solium cysts present in the brain. iii. determine the natural regression of cerebral t. solium cysts in patients given placebo and their response to treatment at the end of the study.

protocol outline: this is a randomized, double blind study. patients are randomized to receive either albendazole and dexamethasone or placebo. patients receive phenytoin daily starting on day 1 and continuing until seizure free for 1 year. albendazole and dexamethasone or placebo only is administered orally once daily on days 5-15. patients are asked to maintain a diary. patients are followed on day 15 and 30, then every 3 months for 3 years. completion date provided represents the completion date of the grant per oopd records

Eligibility criteria:
protocol entry criteria: --disease characteristics-- * presence of taenia solium infection as demonstrated by serology and head ct head ct showing no more than 20 cysts * at least 2 spontaneous seizures within the last 6 months excluding: absence seizures rolandic seizures bilateral spike wave patterns compatible with genetic epilepsy --prior/concurrent therapy-- * no prior therapy for cysticercosis --patient characteristics-- * age: 16 to 65 * performance status: not specified * hematopoietic: not specified * hepatic: not specified * renal: not specified * neurologic: no focal deficits no motor deficits no cranial nerve lesions history of epilepsy of less than 5 years in duration no head ct evidence of the following: arteriovenous malformations trauma cerebral infarcts or hemorrhages no other focal disease not attributable to cysticercosis no moderate or severe intracranial hypertension no status epilepticus * other: no unstable condition due to systemic disease or cysticercosis not pregnant

Keywords: cysticercosis epilepsy immunologic disorders and infectious disorders neurologic and psychiatric disorders parasitic infection rare disease seizures
the effects of mirtazapine versus placebo on alcohol consumption in male alcohol high consumers

Conditions: Alcohol Dependence

Summary: the purpose of this study is to study the effects of 8 weeks of treatment with mirtazapine on alcohol consumption in alcohol high consuming men. this study is a randomized, double-blind placebo controlled clinical trial with parallel group design(n=59).


Eligibility criteria:
inclusion criteria: * 18-65 years of age * male sex * alcohol high consumption * signed informed consent exclusion criteria: * psychiatric disorders (except nicotine and alcohol dependence) * severe somatic disorders * inadequate knowledge of the swedish language

Keywords: alcohol dependence anti-depressant 5-ht ne
microbiome and papillary thyroid microcarcinoma

Conditions: Papillary Thyroid Microcarcinoma; Microbiome

Summary: it has been shown that gut microbiome and microbiome metabolism can regulate or control the initiation of a cancer process. to the best of the investigators knowledge, no study has directly shown the relationship of the thyroid microcarcinoma to the human microbiome. in this work, the aim is to detect the microbiome in peripheral blood in a patient with a thyroid gland carcinoma, and to correlate it with the disease, compared to the microbiome of a group of patients who did not find another thyroid gland carcinoma

measurements of biological markers and tumor cell motility may be useful in predicting early whether a papillary thyroid microcarcinoma (ptmc) will develop to invasive carcinoma. ideally, patients at high risk of progression may undergo immediate surgery instead of active surveillance and those with a very low likelihood of tumor progression may be included in an active surveillance protocol. future research should focus on the development of new predictive early markers of papillary thyroid carcinoma during patient follow-up. from the above, it is clear the need to develop a new marker that raises the suspicion of possible thyroid microcarcinoma, if it is not preoperatively detected by the needle biopsy method and the patient has the indication for surgery for another benign thyroid disease. to date, there are no absolute biological and clinical parameters distinguishing a low risk from a high risk ptmc. if the fine needle aspiration shows stage v and vi bethesda classification, and there is a high suspicion of ptmc, then questions such as the extent of the surgery, lobectomy or total thyroidectomy are beginning to be raised. the next dilemma is lymphadenectomy. the dilemma is greater if there are enlarged cervical lymph nodes (diameter over 1 cm in diameter of the small axis) and subsequently micromestases are confirmed. another entity is when the cervical lymph nodes are not pathologically enlarged. this clinical situation is often emphasized as 60-80% of ptmc patients have metastases. by correlating a possible difference in the microbiome of a participants peripheral blood preoperatively, together with the imaging data, there may have been another marker of early ptmc detection and patient management planning respectively.

Eligibility criteria:
inclusion criteria: * patients who are going to have surgery for some thyroid disease, benign or malignant exclusion criteria: * recent, less than 3 months, infection of any system * receiving antibiotic or antiviral medication in the previous trimester * patient with chronic virus or bacterial infection * patient with dermatological disease

Keywords: microbiome papillary thyroid microcarcinoma
study to assess drowsiness, cognition, fall risk after metaxalone 640 mg and metaxalone 800 mg

Conditions: Healthy Participants

Summary: every participant will receive metaxalone in two (2) stages, one week after the other. a single dose of each metaxalone dose will be taken one (1) time after a high fat meal which must be eaten within 30 minutes. every participant will be given written tests to measure drowsiness, reaction time and thinking process and will also be asked to take walking tests to assess fall risk. participation in this study will last approximately 2-4 weeks.

the screening-baseline visit will include vital signs and urine testing, and a discussion of medications and current medical history. participants will be given written tests to measure drowsiness, reaction time and thinking process and will also be asked to take walking tests to assess fall risk. visit 2 approximately one to two (1 to 2) week(s) later will be the first dosing day (arm 1) after eating the high fat meal. the testing from baseline will be repeated four (4) hours after the medication dose is taken. visit 3 approximately one (1) week later will be the second dosing day (arm 2) after eating the high fat meal. the testing from baseline will be repeated four (4) hours after the medication dose is taken. the end of study safety visit will take place one (1) week after visit 3 by phone with a discussion of any side effects from the drug, recent medications, and any illness or injury experienced since the previous visit. participants will be given end of study and discharge instructions.

Eligibility criteria:
inclusion criteria: * weigh at least 120 pounds at screening * medically healthy with no clinically significant medical co-morbidities impact endpoints exclusion criteria: * current use of any medications known to affect sleep-wake cycle. * known sleep disorder. * current use of cimetidine. * current use of a monoamine oxidase inhibitor (maoi), selective serotonin reuptake inhibitor (ssri), selective norepinephrine reuptake inhibitor (snri), 5- hydroxytryptamine (5-ht) agonist or any drug that has the potential to affect the serotonergic neurotransmitter system (e.g. mirtazapine, trazodone, tramadol). * positive urine test for amphetamines, barbiturates, cocaine, opiates, benzodiazepines, or cannabinoids. * participants taking skeletal muscle relaxants or sedative hypnotics. * participants with gastrointestinal disease affecting absorption. * participants with severe hepatic or renal impairment.
motivational interviewing and medication review in coronary heart disease

Conditions: Coronary Heart Disease

Summary: low medication adherence in patients with coronary heart disease increases mortality. this study investigates if an intervention of medication review and counselling can improve patients' medication adherence and treatment results.

the study will investigate the effects of medication review and motivational interviewing (mi) on patients with coronary heart disease (chd). clinical pharmacists competent in mi and cardiology will conduct medication interviews and medication reviews at the outpatient clinic. the intervention will continue during 9 months, with interviews and reviews as needed. follow-up of results will take place 16 months after inclusion (corresponding to 4 months after the end of intervention). the mi-component will be quality assured by miti 4.2-coding (motivational interviewing treatment integrity). the study will investigate effects on clinical outcomes, medication adherence, patients´ beliefs about medicines and quality of life.

Eligibility criteria:
inclusion criteria: * admitted for angiography * verified coronary artery disease (icd-10 i20-i21) * planned for follow up at the out-patient clinic (standard treatment) * swedish speaking exclusion criteria: * cognitive impairment or any othe condition making interview or phone calls impossible. * non-participation in the standard follow-up * prior participation in this study
n-of-1 trials in children with hypertension

Conditions: Pediatric Hypertension

Summary: the single patient (n-of-1) randomized trial is an underused approach to resolving therapeutic uncertainty by using a patient's own data to inform an individualized treatment plan. the proposed research is designed to assess whether the n-of-1 trial approach improves blood pressure control compared to usual care. this trial aims to advance learning about not only the treatment of pediatric hypertension but also the use of a neglected type of randomized trial to optimize the care of each patient.

pediatric hypertension, a growing problem, often requires prescription of antihypertensive medication. pediatric hypertension specialists lack an evidentiary base on which to establish definitive clinical practice guidelines for first-line therapy. significant practice variation is an unsurprising consequence. routine choice of the same first-line therapy for most patients with hypertension, absent testing other options, may delay correction of blood pressure for months or years. failure to incorporate patient preferences in medical decision-making may also contribute to decreased patient satisfaction and adherence. large parallel-group, comparative effectiveness trials are likely not on the horizon for this population. moreover, heterogeneity of treatment effects would minimize the generalizability of such a trial to all patients. this is a parallel-group, randomized clinical trial to compare the n-of-1 trial approach to usual care in normalizing blood pressure while minimizing exposure to compliance-reducing side effects.

Eligibility criteria:
inclusion criteria: * treating physician determines that pharmacologic therapy is indicated for treatment of hypertension * ambulatory hypertension has been confirmed (off meds) within 12 months of enrollment exclusion criteria: * age \< 10 years * resistant hypertension (requiring ≥ 3 drug therapy) * absolute contraindication or allergy to any of the tested drugs.